EGFR and ovarian carcinoma: While recent approaches with small-molecule tyrosine inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been successful in other cancer indications such as lung and ovarian cancer, they did not provide a significant increase in survival time for glioma patients [10,11].